搜尋結果
AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen.
2024年8月2日 · Region. Development Stage. 「Lenvima/Kisplyx」 (lenvatinib/E7080) Anticancer agent / kinase inhibitor In-house Oral. In combination with anti-PD-1 therapy pembrolizumab, joint development with Merck & Co., Inc., Rahway, NJ, USA, through an affiliate (Additional Indication) Hepatocellular carcinoma (in combination with transcatheter arterial ...
AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen.
This research will combine the world’s most advanced ubiquitin-proteasome research as conducted in the graduate school with drug discovery knowledge fostered by Eisai, for the development of new protein degradation technology towards proteins targeted by drugs and the promotion of drug discovery research based on this technology.
The rolling submission of a Biologics License Application (BLA) for maintenance dosing of a subcutaneous injection formulation, which is being developed to enhance convenience for patients, was initiated in the U.S. under Fast Track status in May 2024. About the Collaboration between Eisai and Biogen for AD.
Eisai is committed to utilizing this venture investment business to accelerate flexible collaboration with academia, drug discovery ventures, and IT ventures, to create innovative new medicines targeting diseases with high unmet medical needs.
Notable data includes an oral presentation on biomarker analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial (NCT02811861), which evaluated lenvatinib (LENVIMA®) plus pembrolizumab (KEYTRUDA®) versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (Abstract #4504).
